These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28849261)

  • 21. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
    Giuliani J; Fiorica F; Sacchetto A; Franceschini G; Vaccari F; Bonetti A
    J Oncol Pharm Pract; 2021 Mar; 27(2):445-447. PubMed ID: 33356990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
    Mercadante S
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.
    Kwon MY; Cho HN; Koo DH; Lee YG; Oh S; Lee SS
    Korean J Intern Med; 2018 May; 33(3):577-584. PubMed ID: 28111431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
    Portenoy RK; Taylor D; Messina J; Tremmel L
    Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance.
    Kaplan S; Bergamasco A; Sergerie M; Castilloux AM; Moride Y
    Drug Saf; 2020 Feb; 43(2):163-177. PubMed ID: 31691255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients.
    Kwon MY; Lee MY; Han YJ; Lee SH; Kim EJ; Park S; Lee YG; Koo DH
    PLoS One; 2023; 18(1):e0280212. PubMed ID: 36608031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating breakthrough pain in oncology.
    Mercadante S
    Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
    Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
    Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
    Mercadante S; Masedu F; Valenti M; Aielli F
    Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
    Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
    PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
    Chiou TJ; Chao TC; Chao TY; Huang JS; Chang YF; Wang CH
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1179. PubMed ID: 32721110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
    Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
    Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
    Slatkin NE; Xie F; Messina J; Segal TJ
    J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2019 Sep; 19(3):247-254. PubMed ID: 31177479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
    Überall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.